Back to Archived News
SpectraScience Receives Notification of the Pending Issuance of Two Patents
Wednesday, May 12, 2010
San Diego, CA -- SpectraScience, Inc. (OTCBB: SCIE), a San Diego-based medical device company, announced today that it has been notified that two patents will be issued for its technology. Both patents are for an "optical biopsy system and methods for tissue diagnosis." The patents will be issued by the Japanese Patent office and the European Patent office.
The patent describes using fluorescence spectroscopy to characterize tissue. Native tissue fluorescence ("autofluorescence") without requiring fluorescence-enhancing agents is used to distinguish between normal tissue, hyperplastic tissue, adenomatous tissue, and adenocarcinomas. It also describes a system that provides endoscopic image enhancement for easy location of a tissue site for optical biopsy tissue characterization. The system allows the use of an integrated endoscopic diagnosis and treatment device for immediate diagnosis and treatment without interchanging equipment and relocating the tissue site. The system provides an adjunctive tool to histopathological tissue classification or, alternatively, further treatment that is based on the optical biopsy system diagnosis.
Jim Hitchin, SpectraScience CEO, stated, "We hold approximately 60 patents worldwide that have been issued or are pending on its WavSTAT® Optical Biopsy System and LUMA® Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested."
About SpectraScience, Inc.
SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
Back to Archived News